Sandrock joins board at Atalanta
Plus Imbria staffs C-suite and updates from Berkeley Lights, Akouos and more
Al Sandrock, the former longtime R&D leader of Biogen Inc. (NASDAQ:BIIB), has joined the board of Atalanta Therapeutics Inc. Sandrock joined the boards of Verge Genomics Inc. and Voyager Therapeutics Inc. (NASDAQ:VYGR) last month. Atalanta is developing treatments for CNS diseases using siRNA.
RA Capital-backed Imbria Pharmaceuticals Inc. made a trio of C-suite appointments: Arash Yavari, to the position of CSO, Hugo Fry to that of chief commercial officer, and Komal Joshi as CFO. Yavari is an academic physician at the University of Oxford and senior drug development clinician at Weatherden Ltd., Fry was a managing director at Sanofi (Euronext:SAN; NASDAQ:SNY), and Joshi was CFO at LIB Therapeutics LLC. Imbria is developing heart disease treatments targeting mitochondrial energy production...